← Oncology Approval Tracker

FDA DECISION ·

Trodelvy

sacituzumab govitecan-hziy · Immunomedics

Accelerated approvalNew therapyBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Apr 7, 2021

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults with metastatic triple-negative breast cancer after at least two prior therapies for metastatic disease.

LAMPGEN ANALYSIS

Why it matters

Introduced a Trop-2-directed antibody-drug conjugate after multiple prior lines under accelerated approval.

What research teams should watch

Document metastatic lines and track neutropenia and diarrhea alongside treatment interruptions.

PRIMARY RECORDS

Sources